Combined functional genome survey of therapeutic targets for clear cell carcinoma of the kidney

Hideaki Ito, Kazufumi Honda, Reiko Satow, Eri Arai, Miki Shitashige, Masaya Ono, Tomohiro Sakuma, Shigeru Sakano, Katsusuke Naito, Hideyasu Matsuyama, Tesshi Yamada

Research output: Contribution to journalArticle

Abstract

Objective: Emerging molecular targeting therapeutics have been incorporated into the management of advanced renal cell carcinoma; however, their efficacy remains limited. The aim of this study was to catalog potential therapeutic target molecules for renal cell carcinoma. Methods: We first selected genes up-regulated in clear cell renal cell carcinoma relative to surrounding normal kidney tissues in 10 patients (Study Cohort) using high-density exon arrays that detect all potential transcripts predicted in the human genome. The selected genes were subjected to independent validation in another set of 10 patients (Validation Cohort) using real-time reverse transcriptase polymerase chain reaction and functional screening using small interfering RNA in six clear cell renal cell carcinoma cell lines. Results: We identified 164 genes whose expression was significantly elevated in clear cell renal cell carcinoma (P < 0.0001 [Student's t-test] and at least a 3-fold change in transcription signal). We finally extracted 33 genes required for maintaining cell proliferation in at least two clear cell renal cell carcinoma cell lines. The 33 genes included 13 genes known to be associated with the development/progression of renal cell carcinoma, including CAIX and FLT-1, confirming the robustness of the current strategy. Conclusions: Through a combination of genome-wide expression and functional assays, we identified a set of genes with high potential as targets for drug development. This method is rapid and comprehensive and could be applied to the discovery of diagnostic biomarkers and therapeutic targets for cancers other than clear cell renal cell carcinoma.

Original languageEnglish
Article numberhyr060
Pages (from-to)847-853
Number of pages7
JournalJapanese Journal of Clinical Oncology
Volume41
Issue number7
DOIs
Publication statusPublished - 2011 Jul
Externally publishedYes

Fingerprint

Renal Cell Carcinoma
Genome
Carcinoma
Kidney
Genes
Therapeutics
Cell Line
Surveys and Questionnaires
Human Genome
Reverse Transcriptase Polymerase Chain Reaction
Small Interfering RNA
Real-Time Polymerase Chain Reaction
Exons
Cohort Studies
Biomarkers
Cell Proliferation
Students
Gene Expression
Pharmaceutical Preparations
Neoplasms

Keywords

  • Exon array
  • Functional screening
  • Molecular targeting therapy
  • Renal cell carcinoma
  • Small interfering RNA

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Radiology Nuclear Medicine and imaging

Cite this

Combined functional genome survey of therapeutic targets for clear cell carcinoma of the kidney. / Ito, Hideaki; Honda, Kazufumi; Satow, Reiko; Arai, Eri; Shitashige, Miki; Ono, Masaya; Sakuma, Tomohiro; Sakano, Shigeru; Naito, Katsusuke; Matsuyama, Hideyasu; Yamada, Tesshi.

In: Japanese Journal of Clinical Oncology, Vol. 41, No. 7, hyr060, 07.2011, p. 847-853.

Research output: Contribution to journalArticle

Ito, H, Honda, K, Satow, R, Arai, E, Shitashige, M, Ono, M, Sakuma, T, Sakano, S, Naito, K, Matsuyama, H & Yamada, T 2011, 'Combined functional genome survey of therapeutic targets for clear cell carcinoma of the kidney', Japanese Journal of Clinical Oncology, vol. 41, no. 7, hyr060, pp. 847-853. https://doi.org/10.1093/jjco/hyr060
Ito, Hideaki ; Honda, Kazufumi ; Satow, Reiko ; Arai, Eri ; Shitashige, Miki ; Ono, Masaya ; Sakuma, Tomohiro ; Sakano, Shigeru ; Naito, Katsusuke ; Matsuyama, Hideyasu ; Yamada, Tesshi. / Combined functional genome survey of therapeutic targets for clear cell carcinoma of the kidney. In: Japanese Journal of Clinical Oncology. 2011 ; Vol. 41, No. 7. pp. 847-853.
@article{9ac7cb26ffe643f9aac87c08deff6fd2,
title = "Combined functional genome survey of therapeutic targets for clear cell carcinoma of the kidney",
abstract = "Objective: Emerging molecular targeting therapeutics have been incorporated into the management of advanced renal cell carcinoma; however, their efficacy remains limited. The aim of this study was to catalog potential therapeutic target molecules for renal cell carcinoma. Methods: We first selected genes up-regulated in clear cell renal cell carcinoma relative to surrounding normal kidney tissues in 10 patients (Study Cohort) using high-density exon arrays that detect all potential transcripts predicted in the human genome. The selected genes were subjected to independent validation in another set of 10 patients (Validation Cohort) using real-time reverse transcriptase polymerase chain reaction and functional screening using small interfering RNA in six clear cell renal cell carcinoma cell lines. Results: We identified 164 genes whose expression was significantly elevated in clear cell renal cell carcinoma (P < 0.0001 [Student's t-test] and at least a 3-fold change in transcription signal). We finally extracted 33 genes required for maintaining cell proliferation in at least two clear cell renal cell carcinoma cell lines. The 33 genes included 13 genes known to be associated with the development/progression of renal cell carcinoma, including CAIX and FLT-1, confirming the robustness of the current strategy. Conclusions: Through a combination of genome-wide expression and functional assays, we identified a set of genes with high potential as targets for drug development. This method is rapid and comprehensive and could be applied to the discovery of diagnostic biomarkers and therapeutic targets for cancers other than clear cell renal cell carcinoma.",
keywords = "Exon array, Functional screening, Molecular targeting therapy, Renal cell carcinoma, Small interfering RNA",
author = "Hideaki Ito and Kazufumi Honda and Reiko Satow and Eri Arai and Miki Shitashige and Masaya Ono and Tomohiro Sakuma and Shigeru Sakano and Katsusuke Naito and Hideyasu Matsuyama and Tesshi Yamada",
year = "2011",
month = "7",
doi = "10.1093/jjco/hyr060",
language = "English",
volume = "41",
pages = "847--853",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Combined functional genome survey of therapeutic targets for clear cell carcinoma of the kidney

AU - Ito, Hideaki

AU - Honda, Kazufumi

AU - Satow, Reiko

AU - Arai, Eri

AU - Shitashige, Miki

AU - Ono, Masaya

AU - Sakuma, Tomohiro

AU - Sakano, Shigeru

AU - Naito, Katsusuke

AU - Matsuyama, Hideyasu

AU - Yamada, Tesshi

PY - 2011/7

Y1 - 2011/7

N2 - Objective: Emerging molecular targeting therapeutics have been incorporated into the management of advanced renal cell carcinoma; however, their efficacy remains limited. The aim of this study was to catalog potential therapeutic target molecules for renal cell carcinoma. Methods: We first selected genes up-regulated in clear cell renal cell carcinoma relative to surrounding normal kidney tissues in 10 patients (Study Cohort) using high-density exon arrays that detect all potential transcripts predicted in the human genome. The selected genes were subjected to independent validation in another set of 10 patients (Validation Cohort) using real-time reverse transcriptase polymerase chain reaction and functional screening using small interfering RNA in six clear cell renal cell carcinoma cell lines. Results: We identified 164 genes whose expression was significantly elevated in clear cell renal cell carcinoma (P < 0.0001 [Student's t-test] and at least a 3-fold change in transcription signal). We finally extracted 33 genes required for maintaining cell proliferation in at least two clear cell renal cell carcinoma cell lines. The 33 genes included 13 genes known to be associated with the development/progression of renal cell carcinoma, including CAIX and FLT-1, confirming the robustness of the current strategy. Conclusions: Through a combination of genome-wide expression and functional assays, we identified a set of genes with high potential as targets for drug development. This method is rapid and comprehensive and could be applied to the discovery of diagnostic biomarkers and therapeutic targets for cancers other than clear cell renal cell carcinoma.

AB - Objective: Emerging molecular targeting therapeutics have been incorporated into the management of advanced renal cell carcinoma; however, their efficacy remains limited. The aim of this study was to catalog potential therapeutic target molecules for renal cell carcinoma. Methods: We first selected genes up-regulated in clear cell renal cell carcinoma relative to surrounding normal kidney tissues in 10 patients (Study Cohort) using high-density exon arrays that detect all potential transcripts predicted in the human genome. The selected genes were subjected to independent validation in another set of 10 patients (Validation Cohort) using real-time reverse transcriptase polymerase chain reaction and functional screening using small interfering RNA in six clear cell renal cell carcinoma cell lines. Results: We identified 164 genes whose expression was significantly elevated in clear cell renal cell carcinoma (P < 0.0001 [Student's t-test] and at least a 3-fold change in transcription signal). We finally extracted 33 genes required for maintaining cell proliferation in at least two clear cell renal cell carcinoma cell lines. The 33 genes included 13 genes known to be associated with the development/progression of renal cell carcinoma, including CAIX and FLT-1, confirming the robustness of the current strategy. Conclusions: Through a combination of genome-wide expression and functional assays, we identified a set of genes with high potential as targets for drug development. This method is rapid and comprehensive and could be applied to the discovery of diagnostic biomarkers and therapeutic targets for cancers other than clear cell renal cell carcinoma.

KW - Exon array

KW - Functional screening

KW - Molecular targeting therapy

KW - Renal cell carcinoma

KW - Small interfering RNA

UR - http://www.scopus.com/inward/record.url?scp=79960069629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960069629&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyr060

DO - 10.1093/jjco/hyr060

M3 - Article

VL - 41

SP - 847

EP - 853

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 7

M1 - hyr060

ER -